- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05938699
Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution (Whistler)
Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution - A Double-Masked, Placebo-Controlled, Phase 3b Clinical Trial (Whistler)
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
- Name: Siobhan Garbutt, PhD
- Phone Number: 984-710-5354
- Email: NCX470@nicox.com
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Recruiting
- Mayo Clinic
-
Contact:
- Arthur Sit, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- ≥18 years of age
- Either gender
- Subjects without glaucoma
- Qualifying IOP at Screening Visit
Exclusion Criteria:
- Narrow anterior chamber angles or disqualifying central corneal thickness in either eye
- Clinically significant ocular disease in either eye
- Uncontrolled systemic disease
- Serious hypersensitivity to topical anesthetic eye drops
- Subjects with a known hypersensitivity or contraindications to any of the ingredients in the study medications
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: NCX 470 0.1%
NCX 470 0.1% - one drop in the randomized eye once a day for 8 days
|
NCX 470 0.1% vs Placebo
Other Names:
|
Placebo Comparator: Placebo
Artificial tears - one drop in the randomized eye once a day for 8 days
|
NCX 0.1% vs Placebo
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in AHD
Time Frame: 8 days
|
The primary efficacy endpoint is change from baseline in aqueous humor dynamics AHD). AHD is calculated by using well establish techniques which include capturing the following: Aqueous humor flow rates from fluorescein clearance; Outflow facility using constant weigh tonography; Episcleral venous pressure using a venomanometer. The change in ADH will be calculate in normals following 8 (±1) days of dosing of NCX 470 0.1% compared to placebo. |
8 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Eye Diseases
- Ocular Hypertension
- Glaucoma
- Glaucoma, Open-Angle
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Vasodilator Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Protective Agents
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Antioxidants
- Pharmaceutical Solutions
- Free Radical Scavengers
- Endothelium-Dependent Relaxing Factors
- Gasotransmitters
- Ophthalmic Solutions
- Nitric Oxide
- Lubricant Eye Drops
- Bimatoprost
Other Study ID Numbers
- NCX 470-05
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Open Angle Glaucoma
-
AllerganRecruiting18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA) (ARGOS)Ocular Hypertension | Open-angle GlaucomaUnited States
-
Aerie PharmaceuticalsCompletedOcular Hypertension | Open-angle Glaucoma
-
West Virginia UniversityUniversity of Pittsburgh; University of MichiganWithdrawnOpen-angle Glaucoma
-
Glaukos CorporationUnknownOpen-Angle GlaucomaSpain, Germany, Austria, Turkey
-
Alcon ResearchWithdrawnOpen-Angle Glaucoma
-
Asociación para Evitar la Ceguera en MéxicoUnknown
-
Pharmaceutical Research NetworkCompleted
-
National Eye Institute (NEI)CompletedOpen-Angle Glaucoma
Clinical Trials on NCX 470
-
Nicox Ophthalmics, Inc.RecruitingOcular Hypertension | Open Angle GlaucomaUnited States, China
-
Nicox Ophthalmics, Inc.CompletedOcular Hypertension | Open Angle GlaucomaUnited States
-
Nicox Ophthalmics, Inc.CompletedGlaucoma, Open-Angle | Hypertension, OcularUnited States
-
Nicox Ophthalmics, Inc.Completed
-
Astex Pharmaceuticals, Inc.Completed
-
Avaxia Biologics, IncorporatedCompletedUlcerative ColitisUnited States, Hungary, Belgium, Canada
-
Astex Pharmaceuticals, Inc.CompletedSmall Cell Lung CarcinomaUnited States, Poland
-
Astex Pharmaceuticals, Inc.CompletedMalignant DiseaseUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingLocally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
Forest LaboratoriesTerminated